Vedolizumab-5050: Clinical Perspective of Vedolizumab (Entyvio) use in the Drug Program "Vedolizumab in the Treatment of Ulcerative Colitis" (POLONEZ)

20/04/2020
24/06/2022
EU PAS number:
EUPAS34119
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Vedolizumab-5050_Protocol_redacted

English (1.36 MB - PDF) View document
Study results
Study results

Vedolizumab-5050_RDS_2022-06-14

English (687.3 KB - PDF) View document
Study report
Other information